Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study

Authors:

Abstract
Albiglutide, a selective once-weekly glucagon-like peptide-1 receptor agonist, is being developed for the treatment of type 2 diabetes mellitus. Albiglutide’s effect on cardiac repolarization (QTc interval) was assessed in a randomized, double-blind, placebo-controlled, parallel-group study in healthy subjects with a nested crossover comparison for moxifloxacin.

This publication has 21 references indexed in Scilit: